证券日报网讯安科生物（300009）11月20日在互动平台回答投资者提问时表示，截至2025年11月10日， 公司的股东总数为76058户。 ...

证券日报网讯安科生物（300009）11月20日在互动平台回答投资者提问时表示，博生吉的CD7-CAR-T 待产品获批以后，计划在"一带一路"国家进行直接申报上市的尝试。至于欧美国家，博生吉公司已经和 美国食品药品监督管理局(FDA)有过沟通，可能会使用中国的临床数据在美国直接申报注册临床Ⅱ期， 通过合作伙伴在美国开展Ⅱ期临床试验。商务拓展方面，可能会通过对外授权或者合作开发的方式展 开。 ...

每经AI快讯，有投资者在投资者互动平台提问：隆培促生长素的进展贵司有没有跟进？贵司对维昇药 业的投资是否包含相关上市承诺？ 安科生物（300009.SZ）11月20日在投资者互动平台表示，之前维昇药业与药审中心就生产细节进行沟 通，所以审评处于暂停状态，目前相关沟通已经结束，审评开关已经打开，隆培促生长素处于正常审评 中。 （文章来源：每日经济新闻） ...

在互动平台表示，博生吉的CD7-CAR-T待产品获批以后，计划在一带一路国家进行直接申报上市的尝 试。至于欧美国家，博生吉公司已经和美国食品药品监督管理局（FDA）有过沟通，可能会使用中国的 临床数据在美国直接申报注册临床II期，通过合作伙伴在美国开展II期临床。商务拓展方面，可能会通 过对外授权或者合作开发的方式展开。 ...

Core Viewpoint - Anke Bio (300009.SZ) has officially shipped its long-acting follicle-stimulating hormone in early November, and the company is currently in the process of collecting market sales data and performance metrics [1] Group 1 - The long-acting follicle-stimulating hormone has been shipped as of early November [1] - The company is gathering information on market sales and sales data [1]

Core Viewpoint - Anke Bio (300009.SZ) has officially shipped its long-acting follicle-stimulating hormone in early November, and the company is currently in the process of collecting market sales data and performance metrics [1] Group 1 - The long-acting follicle-stimulating hormone has been shipped as of early November [1] - The company is gathering information on market sales and sales data [1]

Group 1 - The technology and manufacturing sectors, along with healthcare, continue to attract significant investment, particularly in artificial intelligence, semiconductors, and biomedicine [1][2] - In the past week, there were 41 financing events in the domestic primary market, with a total scale of approximately 60.5 billion RMB [3][4] - The most active sectors included artificial intelligence, which completed 6 financing rounds totaling about 5.1 billion RMB, and biomedicine, which completed 4 rounds totaling approximately 0.8 billion RMB [4] Group 2 - Major financing activities were concentrated in Zhejiang, Jiangsu, and Guangdong provinces, with 9, 8, and 8 financing events respectively [5] - Qiming Venture Partners and Matrix Partners were among the most active investment institutions, completing 4 and 2 financing rounds respectively, primarily in technology and healthcare sectors [6] Group 3 - Jiangsu Lizhuo Information Technology received strategic investment to support its AI agriculture technology development and market expansion [7] - Zhiyou Biotech completed several million RMB in Pre-A financing to advance its core product clinical research [8] - Shenzhen Kanos Technology announced approximately 200 million USD in oversubscribed financing to accelerate commercialization and product development [9] Group 4 - Chengdu Zeling Biotech completed B++ financing, focusing on innovative drug development for cancer and autoimmune diseases [11] - Beijing Taihao Biotech secured A round financing to expedite the registration of its infectious disease diagnostic products [17] - Hangzhou Quanzhen Medical completed 100 million RMB in B round financing to enhance AI support for healthcare [19] Group 5 - Guangdong Jufeng Semiconductor completed several billion RMB in financing to support technology innovation and market expansion [30] - Wujie Power completed 300 million RMB in angel financing, focusing on robotics and intelligent operations [31] - Shanghai Yunmai Chip completed over 500 million RMB in A round financing, emphasizing cloud data center technology [35]

安科生物公告，公司高级管理人员姚建平已于2025年11月13日至11月14日通过集中竞价方式，以10.94 元/股均价减持100万股，占公司总股本0.06%，减持计划实施完毕。减持前持股676.22万股，占0.40%， 减持后持股576.22万股，占0.34%，其中无限售条件股份由178.9万股降至78.9万股，有限售条件股份 497.33万股保持不变。此前减持计划于2025年9月4日披露，拟减持上限同为100万股。 ...

南财智讯11月17日电，安科生物公告，公司高级管理人员姚建平先生在减持计划期间通过集中竞价交易 方式合计减持公司股份100万股，占公司总股本的0.06%，本次减持计划已实施完毕。减持后，姚建平 持有公司股份5,762,235股，占公司总股本的0.34%。本次减持行为符合相关法律法规规定，与此前披露 的减持计划一致，不会导致公司控制权变更，不影响公司治理结构和持续经营。 ...

安徽安科生物工程（集团）股份有限公司 关于高级管理人员减持计划实施完成的公告 公司高级管理人员姚建平先生保证向本公司提供的信息内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 安徽安科生物工程（集团）股份有限公司（以下简称"公司"）于2025年9 月4日披露了《关于部分高级管理人员减持计划的预披露公告》（公告编号： 2025-049），公司高级管理人员姚建平先生计划自本公告披露之日起15个交易日 后的3个月内通过集中竞价交易或大宗交易方式减持公司股份100万股（占公司总 股本比例的0.06%）。若在减持计划实施期间公司发生送红股、转增股本、增发新 股或配股等股本变动事项的，本次拟减持股份数量将进行相应调整。 近日，公司收到姚建平先生出具的《关于股份减持计划实施完成告知函》， 姚建平先生于减持计划期间合计减持公司股份100万股，占公司总股本比例的 0.06%，本次减持计划实施完毕。具体情况如下： 一、股东减持基本情况 | 股东名称 | 减持方式 | 减持期间 | 减持均价 | 减持股数 | 占公司总 股本比例 | 股份来源 | | ...